Related references
Note: Only part of the references are listed.Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target
Jieru E. Lin et al.
FUTURE ONCOLOGY (2009)
Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer
Scott A. Waldman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Accelerating drug development using biomarkers: A case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes
Rajesh Krishna et al.
AAPS JOURNAL (2008)
Strategic approach to fit-for-purpose biomarkers in drug development
John A. Wagner
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells
Giovanni M. Pitari et al.
CARCINOGENESIS (2008)
Back to the future: Driving innovation in drug development
J. A. Wagner
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Colorectal Cancer Is a Paracrine Deficiency Syndrome Amenable to Oral Hormone Replacement Therapy
Peng Li et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2008)
Relative quantification based on logistic models for individual polymerase chain reactions
Inna Chervoneva et al.
STATISTICS IN MEDICINE (2007)
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
Richard Gray et al.
LANCET (2007)
The biologic significance of micrometastatic disease and sentinel lymph node technology on colorectal cancer
Douglas Iddings et al.
JOURNAL OF SURGICAL ONCOLOGY (2007)
Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine
Peng Li et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature
Daniel G. Nicastri et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2007)
Prognostic impact of micrometastases in colon cancer - Interim results of a prospective multicenter trial
Anton J. Bilchik et al.
ANNALS OF SURGERY (2007)
The paracrine hormone hypothesis of colorectal cancer
G. M. Pitari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity
Peng Li et al.
GASTROENTEROLOGY (2007)
Adjuvant treatment of colorectal cancer
Brian M. Wolpin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Adjuvant therapy for stage II and III colorectal cancer
Aimery de Gramont et al.
SEMINARS IN ONCOLOGY (2007)
Biornarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs
J. A. Wagner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Targeted agents for adjuvant therapy of colon cancer
Aimery de Gramont et al.
SEMINARS IN ONCOLOGY (2006)
Opinion - A cost-effectiveness approach to the qualification and acceptance of biomarkers
Stephen A. Williams et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: A meta-analysis
Douglas Iddings et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer
Stephanie Schulz et al.
CLINICAL CANCER RESEARCH (2006)
Fit-for-purpose method development and validation for successful biomarker measurement
JW Lee et al.
PHARMACEUTICAL RESEARCH (2006)
Quantification of mRNA using real-time RT-PCR
Tania Nolan et al.
NATURE PROTOCOLS (2006)
Current issues in adjuvant treatment of stage II colon cancer
Thierry Andre et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas
ME Witek et al.
CLINICAL CANCER RESEARCH (2005)
Interruption of homologous desensitization in cyclic guanosine 3′,5′-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins
GM Pitari et al.
CANCER RESEARCH (2005)
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: A conference report
JW Lee et al.
PHARMACEUTICAL RESEARCH (2005)
Drug therapy - Systemic therapy for colorectal cancer
JA Meyerhardt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract
R Birbe et al.
HUMAN PATHOLOGY (2005)
Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer
GS Frick et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2005)
Efficacy of manual dissection of lymph nodes in colon cancer resections
HG Brown et al.
MODERN PATHOLOGY (2004)
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
AB Benson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group
A Figueredo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
T Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor
SL Carrithers et al.
KIDNEY INTERNATIONAL (2004)
The staging of colorectal cancer: 2004 and beyond
CC Compton et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2004)
Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of Intergroup trial INT-0089
TE Le Voyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Bacterial enterotoxins are associated with resistance to colon cancer
GM Pitari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined
RS Swanson et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Targeted inactivation of the mouse guanylin gene results in altered dynamics of colonic epithelial proliferation
KA Steinbrecher et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells
GM Pitari et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Expression of guanylin is downregulated in mouse and human intestinal adenomas
KA Steinbrecher et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
New directions in the treatment of colorectal cancer: a look to the future
A Sobrero et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
